

# Ellina Lytvyak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/311859/publications.pdf>

Version: 2024-02-01

31  
papers

561  
citations

687363

13  
h-index

642732

23  
g-index

32  
all docs

32  
docs citations

32  
times ranked

832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health, 2015, 15, 1195.	2.9	147
2	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 173-182.	3.7	46
3	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	2.8	37
4	Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 1101-1108.	0.4	34
5	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
6	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International, 2022, 42, 607-614.	3.9	26
7	Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. Inflammatory Bowel Diseases, 2019, 25, 403-409.	1.9	25
8	Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS ONE, 2018, 13, e0193960.	2.5	22
9	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	3.7	21
10	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2295-2304.e2.	4.4	18
11	Healthy Alberta Communities: Impact of a three-year community-based obesity and chronic disease prevention intervention. Preventive Medicine, 2013, 57, 955-962.	3.4	17
12	Combination antiretroviral studies for patients with primary biliary cirrhosis. World Journal of Gastroenterology, 2016, 22, 349.	3.3	17
13	Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	3.9	15
14	Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. Canadian Liver Journal, 2019, 2, 31-44.	0.9	11
15	Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 459-464.	1.8	11
16	Measuring the Progress of Capacity Building in the Alberta Policy Coalition for Cancer Prevention. Health Promotion Practice, 2014, 15, 496-505.	1.6	10
17	Walking and type 2 diabetes risk using CANRISK scores among older adults. Applied Physiology, Nutrition and Metabolism, 2017, 42, 33-38.	1.9	9
18	Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. Journal of Crohn's and Colitis, 2020, 14, 1653-1661.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation. <i>Liver International</i> , 2021, 41, 1879-1883.	3.9	9
20	Impact of a 3-year multi-centre community-based intervention on risk factors for chronic disease and obesity among free-living adults: the Healthy Alberta Communities study. <i>BMC Public Health</i> , 2016, 16, 344.	2.9	8
21	FRI-029-Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?. <i>Journal of Hepatology</i> , 2019, 70, e396-e397.	3.7	8
22	Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization. <i>Crohn's &amp; Colitis</i> 360, 2020, 2, .	1.1	8
23	Vitamin D Is Associated with Clinical Outcomes in Patients with Primary Biliary Cholangitis. <i>Nutrients</i> , 2022, 14, 878.	4.1	8
24	Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. <i>Hepatology</i> , 2022, 76, 303-316.	7.3	6
25	Examining the Promotion of Healthy Eating among Exercise Specialists: A Cross-sectional Study. <i>Canadian Journal of Dietetic Practice and Research</i> , 2015, 76, 76-80.	0.6	4
26	558 - International Experience of Vedolizumab in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, S-1097.	1.3	2
27	Ambulatory Activity and Diabetes Risk From the Alberta Older Adult Health Behavior (ALERT) Study. <i>Canadian Journal of Diabetes</i> , 2014, 38, S73.	0.8	0
28	Sa1006 " Adherence to Guidelines and Best Practices for IBD Flare Management and Corticosteroid Administration: A Retrospective Chart Review. <i>Gastroenterology</i> , 2019, 156, S-251-S-252.	1.3	0
29	Tu1796 " Management of Inflammatory Bowel Disease Patients with Clinical Care Pathways Reduces Emergency Department Utilization. <i>Gastroenterology</i> , 2019, 156, S-1127.	1.3	0
30	Sa1831 " Elevated Serum Immunoglobulin G4 Fails to Prognosticate Inflammatory Bowel Disease Outcomes in Primary Sclerosing Cholangitis Patients. <i>Gastroenterology</i> , 2019, 156, S-419-S-420.	1.3	0
31	Tu1804 " Effectiveness of a Remote Patient Monitoring Protocol Aiming to Improve Care for Ulcerative Colitis Patients. <i>Gastroenterology</i> , 2019, 156, S-1130.	1.3	0